BURGESS, LAURENCE E.,伯吉斯 罗伦斯E,伯吉斯 羅倫斯E,GRONEBERG, ROBERT D.,葛朗尼伯格 罗伯特D,葛朗尼伯格 羅伯特D,HARVEY, DARREN M.,哈维 德伦M,哈維 德倫M,HUANG, LILY,黄莉莉,黃莉莉,KERCHER, TIMOTHY,科雀尔 提姆锡,科雀爾 提姆錫,KRASER, CHRISTOPHER F.,凯雷瑟 克里斯多夫F
申请号：
TW100113047
公开号：
TWI494314B
申请日:
2011.04.14
申请国别(地区):
TW
年份:
2015
代理人:
摘要：
Compounds of FormulaI:and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3, R4, R5, R6, R7, X1and X2have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.式I化合物及其立體異構體和藥學上可接受的鹽和溶劑化物是一種或多種JAK激酶的抑制劑,並且用於治療自身免疫疾病、炎性疾病、移植器官、組織和細胞的排斥、以及血液系統疾患和惡性疾病及它們的併發症:其中R1、R2、R3、R4、R5、R6、R7、X1和X2具有說明書中給出的含義。
